SciELO - Scientific Electronic Library Online

 
vol.43 issue5Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343

Abstract

ESTEVE-PITARCH, Erika  and  GRUPO MULTIDISCIPLINAR OTAC HOSPITAL UNIVERSITARI DE BELLVITGE et al. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion. Farm Hosp. [online]. 2019, vol.43, n.5, pp.151-157.  Epub Oct 14, 2019. ISSN 2171-8695.  https://dx.doi.org/10.7399/fh.11170.

Objective

To determine the percentage of patients given standard doses of piperacillin/tazobactam or meropenem by continuous infusion who achieved the target pharmacokinetic/pharmacodynamic (PK/PD) index, which was defined as free concentrations four times more than the minimum inhibitory concentration (CMI) for 100% of the dosing interval (100% fT≥ 4 x MIC).

Method

Preliminary data from a larger prospective clinical study analysing the PK/PD behaviour of β-lactams antibiotics continuous infusion (CI) in critical patients. The study was conducted in the intensive care units of a tertiary university hospital for adults (June 2015-May 2017). Inclusion criteria: normal renal function (glomerular renal function (GFR) CKD-EPI formula ≥ 60 mL/min/1.73 m2) and treatment with standard dose β-lactams CI. Concentrations at steady state (Css) conditions were determined using UHPLC-MS/MS. We selected the highest susceptible MIC for all likely organisms according to European Commitee on Antimicrobial Susceptibility Testing’s (i.e. piperacillin/tazobactam: 8 mg/L for enterobacteriaceae and 16 mg/L for Pseudomonas aeruginosa; meropenem: 2 mg/L for any microorganism). In addition, a subanalysis of patients was conducted using actual MIC values.

Results

61 patients were enrolled (25 to meropenem and 36 to pipe-racillin/tazobactam). Average age was 59 (15) years and median GFR rate was 95 mL/min/1.73 m2 (83-115). Median meropenem and pipe-racillin free concentrations were 16 mg/L (11-29) and 40 mg/L (21-51), respectively.

88% of patients treated with meropenem reached the PK/PD target, without differences between both microorganisms. For piperacillin/tazobactam, 61% and 11% of patients reached the target, with enterobacteria-ceae and Pseudomonas as suspected microorganisms, respectively. The pathogen was isolated in 35 (57%) patients: 94% reached the target PK/ PD, without differences between both antibiotic therapies.

Keywords : Beta-lactams; Critical care; Pharmacokinetics; Drug monitoring; Piperacillin; Meropenem.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )